From: Cryptococcus neoformans, a global threat to human health
Pathogen | Final ranking of pathogens | Geographic distribution | Mortality |
---|---|---|---|
Critical priority group | Â | Â | Â |
 Cryptococcus neoformans | 1 | Global | 41–61% |
 Candida auris | 2 | Global | 29–53% |
 Aspergillus fumigatus | 3 | Global | 47–88% |
 Candida albicans | 4 | Global | 20–50% |
High priority group | Â | Â | Â |
 Nakaseomyces glabrata (Candida glabrata) | 5 | Global | 20–50% |
 Histoplasma spp. | 6 | Global | 21–53% (HIV/AIDS patients) 9–11% (immunosuppressed patients) |
 Eumycetoma causative agents | 7 | Global | Lack of data. Thought to be low |
 Mucorales | 8 | Global | 23–80% (adult patients) 72.7% (pediatric patients) |
 Fusarium spp. | 9 | Global | 43–67% |
 Candida tropicalis | 10 | Global | 55–60% (adult patients) 26–40% (pediatric patients) |
 Candida parapsilosis | 11 | Global | 20–45% |
Medium priority group | Â | Â | Â |
 Scedosporium spp. | 12 | Global | 42–46% |
 Lomentospora prolificans | 13 | Global | 50–71% (adult patients) 50% (immunocompromised children) |
 Coccidioides spp. | 14 | Americas | 2–13% |
 Pichia kudriavzeveii (Candida krusei) | 15 | Global | 44–67% |
 Cryptococcus gattii | 16 | Global | 10–23% (CNS infections) 15–21% (pulmonary infections) |
 Talaromyces marneffei | 17 | South-East Asia, China | 12–21% |
 Pneumocystis jirovecii | 18 | Global | 0–100% |
 Paracoccidioides spp. | 19 | Central and South America | 3–23% |